Al-Achkar Walid, Azeiz Ghassan, Moassass Faten, Wafa Abdulsamad
Human Genetics Division, Department of Molecular Biology and Biotechnology, Atomic Energy Commission of Syria, 17th Nissan St., Kafersouseh, 6091, Damascus, Syria,
Med Oncol. 2014 May;31(5):889. doi: 10.1007/s12032-014-0889-4. Epub 2014 Mar 27.
In the present study, we investigated the associations of polymorphisms in cytochrome P450 gene (CYP1A1), glutathione S-transferase genes (GSTM1 and GSTT1) with chronic myelogenous leukemia (CML). A total of 126 patients with CML and 172 healthy volunteers were genotyped, and the DNA was isolated from their blood samples. The polymorphisms were assessed by polymerase chain reaction (PCR) restriction fragment length polymorphism-based methods and multiplex PCR. Logistic regression analyses showed significant risk of CML associated with CYP1A1 Val allele [odds ratio (OR) 3.3, 95% confidence intervals (CI) 1.96-5.53], (p < 0.0001) while CYP1A1 Val/Val homozygotes were observed only in the CML patients. There was statistically significant difference in the frequency of GSTM1 and GSTT1 null genotypes. The GSTT1-null genotype was slightly higher in 27% of CML cases and 16.7% of controls (OR 1.98, 95% CI 1.12-3.5) (p < 0.020). The GSTM1 null was higher in 42.8% of CML cases and 22.7% of controls (OR 2.55, 95% CI 1.54-4.22) (p < 0.00024). The individuals carrying CYP1A1 Ile/Val (AG) and GSTM1 null genotype have 9.9 times higher risk to be CML than those carrying CYP1A1 Ile/Ile (AA) and GSTM1 present genotype (OR 9.9, 95% CI 2.7-36.3) (p < 0.0001). This suggests that the association of the GSTM1 null genotype, either alone or in combination with GSTT1 null, with CYP1AI heterozygous leads to the CML risk.
在本研究中,我们调查了细胞色素P450基因(CYP1A1)、谷胱甘肽S-转移酶基因(GSTM1和GSTT1)多态性与慢性粒细胞白血病(CML)之间的关联。对总共126例CML患者和172名健康志愿者进行了基因分型,并从他们的血液样本中分离出DNA。通过基于聚合酶链反应(PCR)限制片段长度多态性的方法和多重PCR对多态性进行评估。逻辑回归分析显示,CML的显著风险与CYP1A1 Val等位基因相关[比值比(OR)3.3,95%置信区间(CI)1.96 - 5.53],(p < 0.0001),而仅在CML患者中观察到CYP1A1 Val/Val纯合子。GSTM1和GSTT1无效基因型的频率存在统计学显著差异。GSTT1无效基因型在27%的CML病例和16.7%的对照中略高(OR 1.98,95% CI 1.12 - 3.5)(p < 0.020)。GSTM1无效在42.8%的CML病例和22.7%的对照中更高(OR 2.55,95% CI 1.54 - 4.22)(p < 0.00024)。携带CYP1A1 Ile/Val(AG)和GSTM1无效基因型的个体患CML的风险比携带CYP1A1 Ile/Ile(AA)和GSTM1现有基因型的个体高9.9倍(OR 9.9,95% CI 2.7 - 36.3)(p < 0.0001)。这表明GSTM1无效基因型单独或与GSTT1无效联合,与CYP1AI杂合导致CML风险。